CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 567 enrolled
Drug / intervention
Vareniclinedrug
Likely dose
Varenicline 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00669240
NCT00669240N/ACompleted
CompareCT.gov

Champix Observational Investigation In The Cessation of Smoking

Pfizer·observational·Posted Apr 30, 2008·Updated Jul 23, 2015

In Brief

An observational study evaluating Varenicline for Smoking Cessation. Completed, enrolled 567 participants across 52 sites in 4 countries.

Detailed Summary

The purpose of this study is to determine the safety and efficacy of varenicline in the real-world environment of smokers attending primary care in routine clinical practice with the addition of being offered behavioral support "Life REWARDS"TM. This is a non-interventional study.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesBelgium, Greece, Hungary, Slovenia
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 30, 2008
Enrollment StartNov 1, 2007
Primary CompletionJun 1, 2009
Study CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 18.2 years ago

Interventions

Vareniclinedrug

According to the approved Summary of Product Characteristics (SmPC), patients will be required to orally take 0.5 mg once daily for the first 3 days and titrate up to 0.5 mg twice daily for days 4 - 7. From day 8 to the end of treatment patients should take 1 mg twice daily. Patients who cannot tolerate adverse effects of Champix may have the dose lowered temporarily or permanently to 0.5 mg twice daily. Patients should be treated for 12 weeks. Treatment should start 1 - 2 weeks prior to quitting smoking.